- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
MPNs | Clinical
Phlebotomy Requirements Diminished With Rusfertide for Polycythemia Vera
June 15, 2021
The hepcidin mimetic rusfertide is suggested to reduce the need for phlebotomy in patients with polycythemia vera, according to the results of the phase 2 PTG-300-04 trial presented during the European Hematology Association 2021 Virtual Congress.
Important Safety Data Evaluated in Meta-Analysis of Myelofibrosis
June 15, 2021
Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.
Cardiovascular Risk Management Requires Further Improvement for MPNs
June 14, 2021
A proportion of patients with myeloproliferative neoplasms were not prescribed medications needed for the management of comorbidities in the United Kingdom, a poster presented during the 2021 European Hematology Association Virtual Congress showed.
Transfusion Independence at 24 Weeks Linked to Improved OS on Momelotinib in Myelofibrosis
June 11, 2021
Subgroup analyses from the the phase 3 SIMPLIFY 1 and SIMPLIFY 2 trials show that achievement of transfusion independence by the 24th week of treatment is associated with an improvement in overall survival compared with continued transfusion dependence at that time point.
Investigators Recommend Allo-Transplant for Eligible Patients With Myelofibrosis
June 10, 2021
Based on a systematic review and meta-analysis , investigators say allogeneic hematopoietic cell transplant should be considered a standard of care option for patients with high-risk myelofibrosi.
FDA Accepts NDA For Pacritinib to Treat Myelofibrosis and Thrombocytopenia
June 01, 2021
The FDA has accepted and granted priority review to a new drug application for pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as a platelet count less than 50x109/L.
BLA Resubmission for Ropeginterferon alfa-2b Accepted by FDA for Treatment of Patients with PV
May 21, 2021
After receiving a complete response letter by the FDA, an approval application for ropeginterferon alfa-2b for treatment for patients with polycythemia vera. has been resubmitted to the FDA.
The Management of Myeloproliferative Neoplasms in Pregnant Women
May 18, 2021
In an interview with Targeted Oncology, Naseema Gangat, MD, MBBS, discussed her recommendations for managing pregnant patients with myeloproliferative neoplasms.
Research Supporting the Use of Ruxolitinib for the Treatment of Myelofibrosis
May 18, 2021
Haris Ali, MD, discusses research supporting the use of ruxolitinib for the treatment of myelofibrosis.
Ruxolitinib Continues to Show Strong Efficacy as Frontline Therapy in Myelofibrosis
May 16, 2021
The most recent data on ruxolitinib support its continued use as frontline treatment of patients with myelofibrosis.